
The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …

Guidance for patients on coming off antidepressants needs to be updated, according to the Royal College of Psychiatrists (RCP). Current …

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …

Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …

Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …

Oklahoma state prosecutors have accused Johnson & Johnson of engaging in a “cynical, deceitful, multibillion-dollar brainwashing campaign” to boost sales …

Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for chronic pain, Italian prosecutors say. …

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …

Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …

Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration …

Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …

Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …